Intravascular tumor necrosis factor α blockade reverses endothelial dysfunction in rheumatoid arthritis

Cardillo, Carmine; Schinzari, Francesca; Mores, Nadia; Mettimano, Marco; Melina, D; Zoli, Angelo; Ferraccioli, Gianfranco

doi:10.1016/j.clpt.2006.05.011

Cited by 58 publications

(35 citation statements)

References 28 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a very recent study performed by Bosello et al (19) also revealed very similar results as in the study of Gonzales et al (18). Cardillo et al (21) evaluated the effects of infliximab on the endothelial functions in early RA patients (duration of symptoms <12 months) using plethysmography and concluded that infliximab infusion for 60 minute duration restore endothelium-dependent vasodilator capacity. In all of these studies, in contrast to ours, MTX was continued as a DMARD therapy along with the anti-TNF-α treatment which may also interfere with the endothelial response.…”

Section: Discussionsupporting

confidence: 65%

“…Since anti-TNF-α treatment reduces disease activity in RA patients and accepted as a useful new therapeutic option in RA (14,15), it was assumed that TNF-α blockers may also improve arterial elasticity and as a result vascular functions. With this regard, in several studies, the validity of this hypothesis was investigated with different type of TNF-α blockers such as infliximab (17)(18)(19)21) and ENC (16,20,22).…”

Section: Discussionmentioning

confidence: 99%

“…TNF-α inhibitors have recently been demonstrated to be very effective in controlling signs and symptoms in approximately two thirds of patients with RA (14,15). In recent years, the effects of different types of TNF-α inhibitors on endothelial functions were investigated in a limited number of studies and controversial results were published (16)(17)(18)(19)(20)(21)(22).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis

Tıkız

Arslan²,

Pırıldar

et al. 2010

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 65%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis

Tıkız

Arslan²,

Pırıldar

et al. 2010

Anadolu Kardiyol Derg

View full text Add to dashboard Cite

“…34 There is now a gradual realisation that effective immunosuppression may actually be the key to reducing CVS disease in RA, and that the increased use of drugs such as methotrexate, regardless of steroid doses, has reduced CVS morbidity and mortality. 28 Likewise, anti-TNF alpha therapy has been shown to improve lipid profiles and endothelial function, 35 as well as reducing the likelihood of a first MI. 36 TNF alpha is directly implicated in the pathogenesis of atherosclerotic plaques, 37 and lowering TNF alpha levels per se should have a positive effect on the circulation.…”

Section: Drug Therapymentioning

confidence: 99%

Cardiovascular disease – the silent killer in rheumatoid arthritis

Kumar

Armstrong

2008

Clinical Medicine

View full text Add to dashboard Cite

-Rheumatoid arthritis (RA) is a multisystem disease with high rates of morbidity and mortality. In recent years, there has been increasing focus on the growing rates of cardiovascular disease (CVD) in RA, over and above expected levels allowing for 'traditional' risk factors. In this paper the impact of CVD in RA, the relative contributions of traditional risk factors and novel risk factors (including homocysteine, oxidised lowdensity lipoprotein, high-sensitivity C-reactive protein and leptin), and the need to address cardiovascular risk in the fight against premature death from coronary artery and stroke disease in RA are discussed.KEY WORDS: C-reactive protein, cardiovascular disease, coronary artery disease, homocysteine, hyperlipidaemia, hypertension, rheumatoid arthritis IntroductionRheumatoid arthritis (RA) is a chronic systemic inflammatory disorder that affects at least 1% of women and 0.44% of men in the UK. 1 Severe RA carries a five-year survival rate similar to three vessel coronary artery disease (CAD) or stage four Hodgkin's disease. 2 Although the increased mortality has been linked with disease severity, disability and the presence of extra-articular disease, accelerated atherosclerosis leading to CAD remains the main reason for the increased death rate. 3 Traditional risk factors are heavily implicated, but there is also increasing awareness that the chronic inflammation and endothelial damage associated with rheumatoid disease itself has a role to play, and this may enhance the undesirable effects of traditional factors (Fig 1). 4 Cardiovascular disease in rheumatoid arthritisPatients who suffer from RA have a greater incidence of diastolic hypertension, angina and stroke, and have an increased risk of sub-clinical vascular disease as shown by a higher prevalence of carotid disease, peripheral arterial disease and electrographic abnormalities. 5,6 Deaths from cardiovascular disease (CVD) occur earlier than in the general population, and it has been suggested that the increased risk of ischaemic heart disease (IHD) in RA precedes the onset of clinical rheumatoid disease. 4,7 Traditional risk factors for atherosclerosis, such as smoking, hypercholesterolaemia, hypertension, diabetes and a sedentary lifestyle may be common or indeed more common in RA than in the population as a whole, but do not account for all of the increase in circulatory disease. There is now a large body of evidence 8 that the chronic inflammatory state can enhance the deleterious effects of some traditional risk factors, such as the association between systemic inflammation and arterial wall stiffness in hypertension, 9 or the proatherogenic lipid profile (high LDL and lipoprotein(a), low HDL) seen with increasing rheumatoid disease activity, 10 as well as introducing some new ones. The burden of addressing IHD in RA is therefore divided between rigorous control of traditional risk factors, and effective disease control through immunosuppression. How does systemic rheumatoid disease accelerate cardiovascular damage...

show abstract

“…TNF-a blockade appears to ameliorate endothelial dysfunction and downregulate mediators of angiogenesis such as VEGF [Cardillo et al 2006;Macias et al 2005]. Furthermore, infliximab reduces circulating VEGF levels and leads to an observed reduction in number of blood vessels in patients with rheumatoid arthritis [Maini and Feldmann, 2002].…”

mentioning

confidence: 99%

Ulcerative colitis, infliximab, and hepatic epithelioid hemangioendothelioma: who is to blame? Case Report

Chang

Marks

Nagorney

et al. 2010

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Epithelioid hemangioendothelioma (EH) is a rare vascular neoplasm that was first described by Weiss and Enzinger [1982]. The natural history and clinical course of EH is largely unknown given its rarity, but its malignant potential is thought to range between that of a benign hemangioma to a malignant angiosarcoma [Woodall et al. 2008;Mehrabi et al. 2006;Uchimura et al. 2001]. Primary disease can involve soft tissue and visceral organs to include heart, spleen, lung, bone, and lymph nodes [Woodall et al. 2008;Mehrabi et al. 2006]. Primary malignant hepatic epithelioid hemangioendothelioma (HEH) is an exceptionally rare tumor with a reported incidence of less than 0.1 per 100,000, with less than 440 published reports in the literature [Mehrabi et al. 2006]. The exact etiopathogenesis of HEH is unknown but possible etiologic factors have been described to include oral contraceptives, vinyl chloride, asbestos, hepatic trauma, viral hepatitis, primary biliary cirrhosis, and alcohol consumption [Mehrabi et al. 2006].

show abstract

Intravascular tumor necrosis factor α blockade reverses endothelial dysfunction in rheumatoid arthritis

Cited by 58 publications

References 28 publications

The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis

The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis

Cardiovascular disease – the silent killer in rheumatoid arthritis

Ulcerative colitis, infliximab, and hepatic epithelioid hemangioendothelioma: who is to blame? Case Report

Contact Info

Product

Resources

About